Suppr
超能文献

Cancel the denosumab holiday.

作者信息

McClung M R

机构信息

Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR, 97210, USA.

出版信息

Osteoporos Int. 2016 May;27(5):1677-82. doi: 10.1007/s00198-016-3553-3. Epub 2016 Mar 1.

DOI:10.1007/s00198-016-3553-3

PMID:26932443

Abstract

摘要

相似文献

Cancel the denosumab holiday.

Osteoporos Int. 2016 May;27(5):1677-82. doi: 10.1007/s00198-016-3553-3. Epub 2016 Mar 1.

Denosumab after 8 years.

Osteoporos Int. 2015 Dec;26(12):2759-61. doi: 10.1007/s00198-015-3347-z. Epub 2015 Oct 16.

[Osteoporosis treatment can be discontinued based on an individual assessment].

Ugeskr Laeger. 2017 Jan 9;179(2).

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.

Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.

Consult Pharm. 2018 Mar 1;33(3):142-151. doi: 10.4140/TCP.n.2018.142.

Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):354-358. doi: 10.1210/jc.2016-3170.

Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Osteoporos Int. 2024 Oct;35(10):1869-1870. doi: 10.1007/s00198-024-07218-x. Epub 2024 Aug 9.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Osteoporos Int. 2015 Dec;26(12):2763-71. doi: 10.1007/s00198-015-3179-x. Epub 2015 Jun 12.

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.

Osteoporos Int. 2024 Sep;35(9):1669-1675. doi: 10.1007/s00198-024-07139-9. Epub 2024 Jun 5.

引用本文的文献

Sequential and Long-term Therapy for Osteoporosis.

Curr Osteoporos Rep. 2025 Mar 22;23(1):15. doi: 10.1007/s11914-025-00909-2.

Treatment of Bisphosphonate-Associated Atypical Femur Fracture With a Combination of Teriparatide and a Novel Surgical Technique.

AACE Clin Case Rep. 2024 May 8;10(5):170-173. doi: 10.1016/j.aace.2024.05.001. eCollection 2024 Sep-Oct.

Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society.

Hip Pelvis. 2024 Mar 1;36(1):62-69. doi: 10.5371/hp.2024.36.1.62.

Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.

J Clin Endocrinol Metab. 2024 Apr 19;109(5):1371-1382. doi: 10.1210/clinem/dgad657.

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.

JCI Insight. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790.

Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis.

J Bone Miner Metab. 2022 Nov;40(6):960-967. doi: 10.1007/s00774-022-01357-z. Epub 2022 Aug 8.

Multiple idiopathic external cervical root resorption in patient treated continuously with denosumab: a case report.

BMC Oral Health. 2022 Apr 15;22(1):129. doi: 10.1186/s12903-022-02165-7.

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.

Adv Ther. 2022 Jan;39(1):58-74. doi: 10.1007/s12325-021-01936-y. Epub 2021 Nov 11.

Cortical Thickness Adaptive Response to Mechanical Loading Depends on Periosteal Position and Varies Linearly With Loading Magnitude.

Front Bioeng Biotechnol. 2021 Jun 18;9:671606. doi: 10.3389/fbioe.2021.671606. eCollection 2021.

Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.

J Bone Miner Res. 2021 Sep;36(9):1729-1738. doi: 10.1002/jbmr.4380. Epub 2021 Jun 10.

本文引用的文献

Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.

Osteoporos Int. 2016 May;27(5):1917-21. doi: 10.1007/s00198-015-3458-6. Epub 2015 Dec 22.

Multiple clinical vertebral fractures following denosumab discontinuation.

Osteoporos Int. 2016 May;27(5):1929-30. doi: 10.1007/s00198-015-3459-5. Epub 2015 Dec 22.

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28.

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.

Osteoporos Int. 2015 Oct;26(10):2401-11. doi: 10.1007/s00198-015-3253-4. Epub 2015 Aug 18.

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Osteoporos Int. 2015 Dec;26(12):2763-71. doi: 10.1007/s00198-015-3179-x. Epub 2015 Jun 12.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.

Osteoporos Int. 2015 Oct;26(10):2479-89. doi: 10.1007/s00198-015-3164-4. Epub 2015 May 28.

Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.

Curr Med Res Opin. 2015;31(7):1391-401. doi: 10.1185/03007995.2015.1053049. Epub 2015 Jun 9.

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

Cancer. 2015 Aug 1;121(15):2537-43. doi: 10.1002/cncr.29327. Epub 2015 Apr 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Cancel the denosumab holiday.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译